DBVT Earnings Date: Mar 25, 2027 (Estimated) — DBV Technologies S.A.
NASDAQ · Healthcare · Biotechnology
Updated
When is DBVT's next earnings date?
DBV Technologies S.A. (DBVT) is expected to report Q4 2026 earnings on Thursday, March 25, 2027 at 5:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.25 on revenue of $664,664.
How did DBVT do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), DBV Technologies S.A. posted EPS of -$0.70 versus the -$0.29 estimate, a miss of 141.4%. Revenue was $1.8M against a $557,583 estimate. The stock's 1-day post-earnings move was -3.4%.
How much does DBVT stock move after earnings?
DBVT beat EPS estimates in 3 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 3.5% (up or down) in the day after earnings.
About DBV Technologies S.A.
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
🤖 AI Earnings Analysis
DBV’s FDA submission of the VIASKIN Peanut BLA is the pivotal catalyst for this biotechnology company; Q3’s $0.14-per-share loss beat estimates by $0.15, but revenue fell to $2 million from $3 million year over year. Results are mixed: regulatory progress matters far more than the noisy beat, while commercial validation remains ahead.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -0.29 | -0.70 | -141.43% | $1.8M | ❌ Miss | -3.38% | — | — |
| 2026-07-16 | Q2 2026 | -0.10 | -0.12 | -20.00% | $700,000 | ❌ Miss | -1.08% | -6.73% | -5.65% |
| 2026-04-30 | Q1 2026 | -0.12 | -0.11 | +8.33% | $900,000 | ✅ Beat | -5.38% | -4.81% | -10.48% |
| 2026-03-26 | Q4 2025 | -0.63 | -0.23 | +63.49% | $645,000 | ✅ Beat | -1.04% | +4.21% | +0.89% |
| 2025-10-28 | Q3 2025 | -0.76 | -0.24 | +68.42% | $2.8M | ✅ Beat | -2.19% | -7.65% | -17.01% |
| 2025-07-29 | Q2 2025 | -0.17 | -0.31 | -82.35% | $1.5M | ❌ Miss | -4.12% | -0.82% | -3.16% |
| 2025-04-30 | Q1 2025 | — | -0.26 | — | $753,000 | — | -4.44% | +5.44% | -7.33% |
| 2025-04-11 | Q4 2024 | -0.22 | -0.22 | +0.00% | $511,000 | ➖ Inline | +6.42% | +21.72% | +50.14% |
Showing last 8 quarters.